Cargando…

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma

BACKGROUND: MAP2K1/2 genes are mutated in approximately 8% of melanoma patients; however, the impact of MAP2K1/2 gene alterations on the efficiency of immunotherapy has not been clarified. This study focused on the correlation between MAP2K1/2 gene mutations and the treatment response. METHODS: Six...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Ting, Zhang, Jie-Ying, Liu, Xin-Yi, Zhou, Yu-Han, Yuan, Si-Yue, Yang, Meng-Mei, Xie, Wen-Zhuan, Gao, Chan, Chen, Yao-Xu, Huang, Meng-Li, Ye, Cheng-Zhi, Chen, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770828/ https://www.ncbi.nlm.nih.gov/pubmed/35069558 http://dx.doi.org/10.3389/fimmu.2021.785526

Ejemplares similares

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
por: Mao, Lili, et al.
Publicado: (2021)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma
por: Zhou, Wencheng, et al.
Publicado: (2022)

Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy
por: Chen, Chen, et al.
Publicado: (2019)

Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis
por: Su, Yue, et al.
Publicado: (2022)

Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma
por: You, Zhixuan, et al.
Publicado: (2022)

Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma
por: Sadozai, Hassan, et al.
Publicado: (2017)

Prognostic Value of an Immunohistochemical Signature in Patients With Head and Neck Mucosal Melanoma
por: Xu, Qing-Qing, et al.
Publicado: (2021)

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
por: Shen, Jianming, et al.
Publicado: (2022)

Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
por: Hoeres, Timm, et al.
Publicado: (2018)

Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
por: Hargadon, Kristian M.
Publicado: (2017)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
por: Yu, Chune, et al.
Publicado: (2019)

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
por: Aris, Mariana, et al.
Publicado: (2017)

An estrogen response-related signature predicts response to immunotherapy in melanoma
por: Lin, Min, et al.
Publicado: (2023)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report
por: Ye, Yanghui, et al.
Publicado: (2021)

Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response
por: Antoranz, Asier, et al.
Publicado: (2022)

DNA Damage Repair in Brain Tumor Immunotherapy
por: Zhao, Shihong, et al.
Publicado: (2022)

Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes
por: Maus, Rachel L. G., et al.
Publicado: (2022)

Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment
por: Aris, Mariana, et al.
Publicado: (2015)

Pattern Recognition Receptors (PRRs) in Macrophages Possess Prognosis and Immunotherapy Potential for Melanoma
por: Zhao, Qihang, et al.
Publicado: (2021)

NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma
por: Li, Hongxia, et al.
Publicado: (2022)

Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy
por: Brentville, Victoria Anne, et al.
Publicado: (2022)

Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
por: Maibach, Fabienne, et al.
Publicado: (2020)

The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy
por: Li, Yayun, et al.
Publicado: (2022)

Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy
por: Tarazona, Raquel, et al.
Publicado: (2016)

Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma
por: Liu, Dan, et al.
Publicado: (2021)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
por: Zhang, Zengfu, et al.
Publicado: (2021)

Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
por: Hu, Yuanyuan, et al.
Publicado: (2022)

Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy
por: Garg, Saurabh K., et al.
Publicado: (2020)

T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
por: Wang, Zhan, et al.
Publicado: (2016)

Anaplastic lymphoma kinase-special immunity and immunotherapy
por: Guo, Ye, et al.
Publicado: (2022)

Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study
por: He, Xiaofeng, et al.
Publicado: (2023)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
por: Mullally, W. J., et al.
Publicado: (2022)

Crosstalk of four kinds of cell deaths defines subtypes of cutaneous melanoma for precise immunotherapy and chemotherapy
por: Wan, Qi, et al.
Publicado: (2022)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

Mapping the Mechanical and Immunological Profiles of Polymeric Microneedles to Enable Vaccine and Immunotherapy Applications
por: Shah, Shrey A., et al.
Publicado: (2022)

Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study
por: Zhong, Weibo, et al.
Publicado: (2022)

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
por: Zheng, Yue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kervvcr6lmf3pf76v6tands3gh